Q3 EPS Forecast for Larimar Therapeutics Lifted by Analyst

Key Points

• William Blair has increased its Q3 2025 EPS estimate for Larimar Therapeutics to ($0.47), improving from the previous estimate of ($0.53).
• Despite the recent upgrade, Larimar's stock has recently seen a 5.9% decline, opening at $4.01, with a year-to-date high of $9.50.
• Institutional investors own 91.92% of Larimar's shares, indicating strong institutional confidence in the company.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at William Blair lifted their Q3 2025 earnings per share estimates for Larimar Therapeutics in a report released on Thursday, August 14th. William Blair analyst M. Minter now anticipates that the company will earn ($0.47) per share for the quarter, up from their prior estimate of ($0.53). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics' Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.69) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS and FY2026 earnings at ($1.50) EPS.

LRMR has been the topic of a number of other research reports. Guggenheim reaffirmed a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, June 24th. Wedbush lowered their target price on Larimar Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research report on Tuesday, June 24th. Citigroup reiterated a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. Finally, JMP Securities lowered their price target on Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating on the stock in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $18.43.

Larimar Therapeutics Price Performance

LRMR traded up $0.22 on Monday, reaching $3.91. The company's stock had a trading volume of 1,421,476 shares, compared to its average volume of 1,828,442. The business's 50 day moving average is $3.38 and its 200 day moving average is $2.79. Larimar Therapeutics has a 1 year low of $1.61 and a 1 year high of $9.50. The stock has a market cap of $323.67 million, a price-to-earnings ratio of -2.51 and a beta of 0.93.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.06.

Insider Buying and Selling at Larimar Therapeutics

In related news, Director James E. Flynn acquired 9,375,000 shares of the business's stock in a transaction that occurred on Thursday, July 31st. The shares were acquired at an average cost of $3.20 per share, with a total value of $30,000,000.00. Following the purchase, the director owned 9,538,945 shares of the company's stock, valued at approximately $30,524,624. The trade was a 5,718.38% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.50% of the company's stock.

Hedge Funds Weigh In On Larimar Therapeutics

Several large investors have recently made changes to their positions in the business. Envestnet Asset Management Inc. increased its position in Larimar Therapeutics by 12.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock worth $137,000 after buying an additional 3,877 shares during the period. Bank of America Corp DE increased its stake in Larimar Therapeutics by 8.1% during the fourth quarter. Bank of America Corp DE now owns 53,190 shares of the company's stock valued at $206,000 after acquiring an additional 3,980 shares during the period. Velan Capital Investment Management LP grew its stake in shares of Larimar Therapeutics by 17.9% in the 2nd quarter. Velan Capital Investment Management LP now owns 33,000 shares of the company's stock valued at $95,000 after purchasing an additional 5,000 shares during the period. American Century Companies Inc. grew its stake in shares of Larimar Therapeutics by 7.8% in the 2nd quarter. American Century Companies Inc. now owns 69,285 shares of the company's stock valued at $200,000 after purchasing an additional 5,001 shares during the period. Finally, BNP Paribas Financial Markets bought a new stake in shares of Larimar Therapeutics in the 4th quarter valued at approximately $25,000. Institutional investors and hedge funds own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.